Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile

Data Sets Demonstrating Efficacy and Quality of Life Profile of SILIQ Presented at 2017 Fall Clinical Dermatology Conference LAVAL, Quebec, Oct. 12, 2017 -- (Healthcare Sales & Marketing Network) -- Ortho Dermatologics, a division of Valeant Pharmaceut... Biopharmaceuticals, Dermatology Ortho Dermatologics, Valeant Pharmaceuticals, SILIQ, brodalumab

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043067

Source: HSMN NewsFeed - October 12, 2017 Category: Pharmaceuticals Source Type: news